Paid Clinical Trials in Mineola, NY

As of June 2026, 127 paid clinical trials are recruiting in Mineola, New York. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.

Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

127 clinical trials

↓ Download CSV

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for Breast Cancer

165 locations incl. Daphne

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06492616·Phase 3·Recruiting

Apply to this trial

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

for Advanced Breast Cancer

Drug: Camizestrant

54 locations incl. Gilbert

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06380751·Phase 3·Recruiting

Apply to this trial

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

for Clinical Stage III Cutaneous Melanoma AJCC v8

26 locations incl. La Jolla

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05896839·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

for Extensive Stage-small Cell Lung Cancer

Drug: Atezolizumab

26 locations incl. Birmingham

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06362252·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

for Hepatocellular Carcinoma

Drug: Atezolizumab

60 locations incl. Tucson

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT06096779·Phase 2·Recruiting

Apply to this trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

for Solid Tumors

18 locations incl. Birmingham

Sponsor: GlaxoSmithKline

Sex: All·Age: 18+

Code: NCT06431594·Phase 1·Recruiting

Apply to this trial

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

for Advanced Esophageal Adenocarcinoma

Drug: Nivolumab

371 locations incl. Little Rock

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06203600·Phase 2, Phase 3·Recruiting

Apply to this trial

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

for Colorectal Cancer

13 locations incl. Los Angeles

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06428409·Phase 1, Phase 2·Recruiting

Apply to this trial

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

for Advanced Malignant Solid Neoplasm

Drug: Peposertib

6 locations incl. Bethesda

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05687136·Phase 1·Recruiting

Apply to this trial

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

for Ovarian Neoplasms

9 locations incl. Scottsdale

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06400472·Phase 1·Recruiting

Apply to this trial

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

for Ganglioneuroblastoma, Nodular

156 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 30

Code: NCT06172296·Phase 3·Recruiting

Apply to this trial

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

for Breast Neoplasms

46 locations incl. Chandler

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06312176·Phase 3·Recruiting

Apply to this trial

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

for Solid Cancer

43 locations incl. Anchorage

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06161025·Phase 2, Phase 3·Recruiting

Apply to this trial

Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence

for Squamous Cell Carcinoma of Head and Neck

6 locations incl. Fayetteville

Sponsor: University of Arkansas

Sex: All·Age: 18 - 100

Code: NCT05952934·Phase 2·Recruiting

Apply to this trial

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

for Endometrial Cancer

17 locations incl. Birmingham

Sponsor: SystImmune Inc.

Sex: All·Age: 18+

Code: NCT06293898·Phase 1·Recruiting

Apply to this trial

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

for Follicular Lymphoma (FL)

Drug: Epcoritamab

58 locations incl. Fresno

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT06191744·Phase 3·Recruiting

Apply to this trial

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

for Muscle Invasive Bladder Urothelial Carcinoma

490 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05987241·Phase 2, Phase 3·Recruiting

Apply to this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

Drug: LY3537982

91 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06119581·Phase 3·Recruiting

Apply to this trial

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

for Multiple Myeloma

Drug: Linvoseltamab

13 locations incl. Los Angeles

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT05828511·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

for Non-small Cell Lung Cancer

Drug: Intismeran autogene

68 locations incl. Anchorage

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06077760·Phase 3·Recruiting

Apply to this trial

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

for Anatomic Stage II Breast Cancer AJCC v8

Drug: Durvalumab

536 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06058377·Phase 3·Recruiting

Apply to this trial

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

for Mantle Cell Lymphoma

237 locations incl. Little Rock

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 60+

Code: NCT05976763·Phase 3·Recruiting

Apply to this trial

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

for Breast Cancer

1208 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 18 - 60

Code: NCT05879926·Phase 3·Recruiting

Apply to this trial

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

for Anatomic Stage I Breast Cancer AJCC v8

955 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05929768·Phase 3·Recruiting

Apply to this trial

Study of AVZO-021 in Patients With Advanced Solid Tumors

for Advanced Solid Tumor

11 locations incl. New Haven

Sponsor: Avenzo Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05867251·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

for Primary IgA Nephropathy

40 locations incl. Alabaster

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT05797610·Phase 3·Recruiting

Apply to this trial

Ladarixin With Sotorasib in Advanced NSCLC

for Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Drug: Sotorasib

6 locations incl. Garden City

Sponsor: NYU Langone Health

Sex: All·Age: 18 - 100

Code: NCT05815173·Phase 1·Recruiting

Apply to this trial

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

for Solid Tumors

11 locations incl. Los Angeles

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT05836324·Phase 1·Recruiting

Apply to this trial

Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

for Acneiform Eruption Due to Chemical

9 locations incl. Irvine

Sponsor: Hoth Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05639933·Phase 2·Recruiting

Apply to this trial

Two Fraction Prostate SBRT With DIL SIB

for Prostate Cancer

2 locations incl. Mineola

Sponsor: NYU Langone Health

Sex: Male·Age: 18+

Code: NCT05864196·Phase 1·Recruiting

Apply to this trial

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

for Metastatic Malignant Solid Neoplasm

22 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05687110·Phase 1·Recruiting

Apply to this trial

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

for Multiple Myeloma

Drug: Iberdomide

44 locations incl. Aurora

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT05827016·Phase 3·Recruiting

Apply to this trial

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

for Non-Small Cell Lung Cancer

Drug: Divarasib

16 locations incl. Duarte

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT05789082·Phase 1, Phase 2·Recruiting

Apply to this trial

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

for Anatomic Stage II Breast Cancer AJCC v8

820 locations incl. Birmingham

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05812807·Phase 3·Recruiting

Apply to this trial

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

for Non Small Cell Lung Cancer

13 locations incl. Santa Monica

Sponsor: Tango Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05887492·Phase 1, Phase 2·Recruiting

Apply to this trial

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

for Anatomic Stage III Breast Cancer AJCC v8

6 locations incl. Boston

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05422794·Phase 1·Recruiting

Apply to this trial

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

for Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Drug: Nivolumab

390 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 5 - 60

Code: NCT05675410·Phase 3·Recruiting

Apply to this trial

Comparison of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2, 3 and 4 Pressure Injuries

for Pressure Ulcers Stage II

14 locations incl. San Diego

Sponsor: ULURU Inc.

Sex: All·Age: 18 - 85·Accepts healthy volunteers

Code: NCT05496296·Recruiting

Apply to this trial

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

for Metastatic Castration-resistant Prostate Neoplasms

Drug: Pasritamig

7 locations incl. Sarasota

Sponsor: Janssen Research & Development, LLC

Sex: Male·Age: 18+

Code: NCT05818683·Phase 1·Recruiting

Apply to this trial

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

for Advanced Malignant Solid Neoplasm

475 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: All ages

Code: NCT05564377·Phase 2·Recruiting

Apply to this trial